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Sulfatase modifying factor 1 (SUMF1) is the gene mutated
in multiple sulfatase deficiency (MSD) that encodes the
formylglycine-generating enzyme, an essential activator of
all the sulfatases. SUMF1 is a glycosylated enzyme that is
resident in the endoplasmic reticulum (ER), although it is
also secreted. Here, we demonstrate that upon secretion,
SUMF1 can be taken up from the medium by several cell
lines. Furthermore, the in vivo engineering of mice liver to
produce SUMF1 shows its secretion into the blood serum
and its uptake into different tissues. Additionally, we show
that non-glycosylated forms of SUMF1 can still be secreted,
while only the glycosylated SUMF1 enters cells, via a
receptor-mediated mechanism. Surprisingly, following its
uptake, SUMF1 shuttles from the plasma membrane to the
ER, a route that has to date only been well characterized
for some of the toxins. Remarkably, once taken up and
relocalized into the ER, SUMF1 is still active, enhancing
the sulfatase activities in both cultured cells and mice
tissues.
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Introduction
The sulfatases are a family of enzymes that catalyze the
hydrolysis of sulfate esters after they have been post-transla-
tionally activated (Diez-Roux and Ballabio, 2005). A consen-
sus sequence in their catalytic domain contains a cysteine
that is modified into formylglycine (FGly) within the endo-
plasmic reticulum (ER). The FGly is essential for sulfatase
activity, as in its hydrate form, FGly is able to accept the
sulfate group from the substrate and subsequently remove it
from the enzyme (Schmidt et al, 1995; Boltes et al, 2001). We
and others have identified the gene, sulfatase modifying
factor 1 (SUMF1), that encodes the FGly-generating enzyme
(Cosma et al, 2003; Dierks et al, 2003). In patients affected by
multiple sulfatase deficiency (MSD), all of their sulfatase
activities are reduced because SUMF1 is hampered in its
function, and mutations in SUMF1 have been found in all
MSD patients analyzed to date (Cosma et al, 2004). The
crystal structure of SUMF1 has been solved and SUMF1 has
been recognized as having an oxygenase function (Dierks
et al, 2005). Overexpression of SUMF1 with sulfatases in
cultured cells via transfection or viral delivery results in a
strong enhancement of the sulfatase activities (Cosma et al,
2003; Fraldi et al, 2007). SUMF1 has been conserved through
evolution and has retained a high homology with the bacter-
ial SUMF1 proteins (Sardiello et al, 2005). Sequence compar-
isons led to the discovery of a paralogue of SUMF1 in the
vertebrate genome, known as SUMF2 (Cosma et al, 2003;
Dierks et al, 2003). The primary sequences of the SUMF1 and
SUMF2 proteins are highly similar. SUMF2 colocalizes with
SUMF1 within the ER and inhibits the enhancing effect of
SUMF1 on the sulfatases (Zito et al, 2005).
SUMF1 is an ER-resident protein. It is glycosylated and its
intracellular form contains high mannose-type oligosacchar-
ides. SUMF1 is also secreted and the secreted form contains a
family of complex-type oligosaccharides (Preusser-Kunze
et al, 2005). Many secreted glycoproteins are cleared from
the plasma through the mannose receptor (MR) (Lee et al,
2002). The MR is an endocytic receptor for glycans that is
ubiquitously expressed. It contains carbohydrate recognition
domains that bind complex-type oligosaccharides such as
terminal fucose and acetylglucosamine residues (Taylor and
Drickamer, 1993). Sulfatases are also secreted into the plasma
and taken up via the mannose-6-phosphate receptor (MPR)
(Ni et al, 2006). The MPR has two forms in the cell, MPR 46
and MPR 300, both of which can transport hydrolases from
the trans-Golgi network to endosomes and/or lysosomes (Ni
et al, 2006).
We now show that endogenous SUMF1 is also secreted.
Furthermore, we demonstrate that both overexpressed and
endogenous SUMF1 can be taken up from the medium by
different cells and from the plasma in tissues of mice en-
gineered to produce SUMF1 in the liver. The uptake of SUMF1
is principally mediated by the MR, and to some extent by the
MPR. The secretion and activity of SUMF1 are independent of
its glycosylation; in contrast, its uptake in cells is impaired
when the protein lacks sugars. Finally, we show here that
once SUMF1 has been taken up, it relocalizes to the ER in
both cultured cells and mice tissues, where it is enzymatically
active, as it can enhance the sulfatase activities.
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Results
SUMF1 is secreted and taken up into the ER
SUMF1 is localized in the ER, where it activates all newly
synthesized sulfatases during or shortly after cotranslational
import (Cosma et al, 2003; Dierks et al, 2003). We have
produced a stable HeLa cell clone that expresses SUMF1-
3xFlag that we have named the HL3xFS1 clone. Three specific
bands of about 42, 39 and 33 kDa that correspond to three
forms of the SUMF1 protein were detected in cellular extracts
from the HL3xFS1 clone using an anti-Flag antibody
(Figure 1A). These different bands of SUMF1 correspond to
its differently glycosylated and/or proteolytically processed
forms, as has been previously demonstrated (Preusser-Kunze
et al, 2005; Zito et al, 2005), and as shown by mass spectro-
metry analysis of protein extracts of the HL3xFS1 clone
(Supplementary Figure 1). SUMF1 was predicted to be se-
creted through large-scale, bioinformatics, high-throughput
screening (Clark et al, 2003). Recently, it was demonstrated
that SUMF1 is secreted when it is overexpressed in HT1080
cells (Preusser-Kunze et al, 2005). As expected, Western
blotting of conditioned medium collected from the HL3xFS1
clone showed secretion of SUMF1-3xFlag into the medium
(Supplementary Figure 2A). In addition, by decorating the
filter with antibodies against several different intracellular
and secreted proteins, we have demonstrated that SUMF1-
3xFlag is actively secreted into the medium, and have
excluded that cell breakage was causing a leakage of SUMF1
into the medium. The overexpression of SUMF1-3xFlag also
does not result in the nonspecific secretion of other endogen-
ous proteins (Supplementary Figure 2A).
The sulfatases are secreted proteins that can be taken up
into all cells of the body via the ubiquitously expressed MPR.
Starting from this observation, we asked whether SUMF1 itself
can also be taken up into cells from the medium. We have in
the laboratory, mouse embryonic fibroblasts (MEFs) from a
Sumf1/ mouse model that we recently generated
(Settembre et al, 2007). Thus, Cos7 and HeLa cells, and
MEFs from wild-type and Sumf1/ mice were incubated in
conditioned medium collected from the confluent HL3xFS1
clone after 12 h of culture. The protein extracts from the
recipient cells were analyzed by Western blotting with an
anti-Flag antibody. SUMF1 was seen to be taken up in all
three cell types (Figure 1B and C, lanes 1–4). Here, the controls
included conditioned and non-conditioned medium
(Figure 1B, lanes 5 and 6) and a sample of the conditioned
medium that was not applied to recipient cells (Figure 1B, lane
7). Protein loading controls were also performed using an
anti–tubulin antibody (Figure 1B and C). To confirm these
results, we performed mass spectrometry analysis of SUMF1-
Flag following its uptake into recipient HeLa cells incubated in
conditioned medium collected from the HL3xFS1 clone.
Protein extracts of the recipient cells were immunoprecipitated
with an anti-Flag antibody and MALDIMS and LC-MS/MS
analysis of the excised, deglycosylated and trypsin-digested
bands were carried out. We clearly detected SUMF1 in bands 1
and 2 and did not detect it in band 3 (Supplementary Figure 1).
These data clearly show that the overexpressed SUMF1
that is secreted into the medium by the HL3xFS1 clone is
taken up into all the cell lines analyzed. By Western blotting,
we detected primarily the uptake of the 42-kDa SUMF1 form,
although under some conditions (e.g. when more protein is
accumulated in the conditioned medium), the 39-kDa SUMF1
form can also be taken up, as shown in the mass spectro-
metry analysis (Supplementary Figure 1).
We then investigated whether secretion and uptake of
SUMF1 occurs only when SUMF1 is overexpressed, or
whether the endogenous protein can also follow the same
route. For this, we used HepG2 cells, which are a human
hepatoma cell line that has been described as being highly
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Figure 1 Secretion and uptake of SUMF1. (A) SUMF1 expression in
the HL3xFS1 clone. Three bands of about 42, 39 and 33 kDa were
detected by Western blotting with an anti-Flag antibody. (B) SUMF1
is secreted from the HL3xFS1 clone and taken up into Cos7 and
HeLa cells. Lanes 1–4: cellular extracts from recipient Cos7 and
HeLa cells incubated with conditioned medium (HL3xFS1M) col-
lected from the HL3xFS1 clone or with control HeLa cell medium, as
analyzed by Western blotting. Lanes 5 and 6: 5% of SUMF1-Flag-
conditioned and control medium used to culture the recipient cells.
Lane 7: 10% of the total SUMF1-Flag-conditioned medium. Western
blotting was carried out with anti-Flag and anti–tubulin antibodies.
(C) SUMF1 is secreted from the HL3xFS1 clone and taken up in
wild-type MEFs and Sumf1/ MEFs. Lanes 1–4: cellular extracts
from recipient cells cultured in SUMF1-Flag-conditioned and control
medium were immunoblotted with anti-Flag and anti–tubulin anti-
bodies. (D) Endogenous SUMF1 is secreted from HepG2 cells and
taken up by MSD fibroblasts. HepG2 cells were cultured for 24, 36
and 48 h. Protein extracts and concentrated media were analyzed by
Western blotting with an anti-human-SUMF1 antibody. MSD1
(p.A149-A173delþp.S359X) and MSD2 (p.M1Rþ rfs) fibroblasts
were cultured for 24 h in concentrated HepG2 medium collected
from two T75 flasks of confluent HepG2 cells. The protein extracts
were analyzed using anti-SUMF1 and anti–tubulin antibodies.
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secretory (Knowles et al, 1980). HepG2 cells were cultured
for 8 h and the conditioned medium was analyzed. A specific,
albeit faint, band was detected by Western blotting using an
anti-human-SUMF1 polyclonal antibody (Supplementary
Figure 2B). Thus, we performed time courses by collecting
the conditioned medium after 24, 36 and 48 h of HepG2
cultivation. A positive signal for SUMF1 was detected in the
cellular pellet and in the concentrated media from these
HepG2 cells using an anti-human-SUMF1 polyclonal antibody
(Figure 1D, top panels). These data demonstrate that endo-
genous SUMF1 is secreted from the HepG2 cells.
Furthermore, for the uptake of this endogenous SUMF1,
confluent recipient MSD fibroblasts were incubated in the
concentrated conditioned medium (collected after 8 h of
culture of 10 million confluent HepG2 cells). Of note, these
two specifically chosen MSD fibroblast cell lines harbor
mutations that cause a frameshift or the early truncation of
SUMF1, and thus they did not have detectable levels of the
endogenous protein. The endogenous SUMF1 of the HepG2
cells was indeed taken up by these MSD cells, as shown by
Western blotting (Figure 1D, lower panels). A cellular extract
of wild-type fibroblasts was also analyzed to indicate the
control levels of SUMF1 in these cells (Figure 1D, lower
panels, WT). The total proteins were normalized using an
anti–tubulin antibody (Figure 1D, lower panels). Thus, the
endogenous SUMF1 in HepG2 cells is secreted into the
medium and can be taken up by human fibroblast cell lines.
We next analyzed the subcellular localization of SUMF1
after its uptake. Sumf1/ MEFs, Cos7 cells and MSD
fibroblasts were incubated with SUMF1-Flag-conditioned
medium. Indirect immunofluorescence using an anti-Flag
antibody demonstrated that SUMF1-Flag localized in the
perinuclear region of Sumf1/ MEFs and Cos7 cells
(Figure 2A and Supplementary Figure 3), with an ER locali-
zation confirmed in Sumf1/ MEFs, Cos7 cells and MSD
cells by its colocalization with the ER marker ERAB using
anti-Flag, anti-SUMF1 and anti-ERAB antibodies (Figure 2B;
Supplementary Figure 3, and data not shown). In addition,
SUMF1 colocalized partly with the endosome markers
LAMP1 and LAMP2, indicating that this uptake could be
mediated via the endosomal compartment (Figure 2B, and
data not shown). The localization of SUMF1 after its uptake
resembles the localization of the endogenous SUMF1 protein
in wild-type MEFs that colocalizes with the ERAB marker
(Figure 2C). Vice versa, a SUMF1-specific signal was not seen
in Sumf1/ MEFs (Figure 2D). These results are striking
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Figure 2 Subcellular localization of SUMF1 taken up into Sumf1/ MEFs cultured in the conditioned medium for 12 h. (A) SUMF1-Flag is
taken up and localizes to the perinuclear region of Sumf1/ MEFs. Internalized SUMF1-Flag is revealed using an anti-Flag antibody. DAPI is
shown as a nuclear marker. (B) Subcellular localization of SUMF1 following its uptake into Sumf1/MEFs. SUMF1-Flag uptake in Sumf1/
MEFs was revealed using an anti-SUMF1 antibody. SUMF1-Flag colocalizes with ERAB (an ER marker) and LAMP1 (an endosome marker),
as seen by confocal microscopy. (C, D) Wild-type and Sumf1/ MEFs were decorated with anti-SUMF1 and anti-ERAB antibodies. Scale
bar, 5mm.
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since they show for the first time that apart from some of the
toxins (Sandvig and van Deurs, 2000), other proteins appear
to be taken up by cells and localized to the ER.
SUMF1 is enzymatically active after its uptake
To determine if SUMF1 is enzymatically active after its
uptake, the activities of different sulfatases were tested in
recipient cells. First, we transfected Cos7 cells with IDS
(iduronate sulfatase), SGSH (sulfamidase) and ARSA (aryl-
sulfatase A) cDNAs. These cells were then incubated with
SUMF1-conditioned medium or with a conditioned medium
containing the fully inactive SUMF1C336R mutant (Cosma
et al, 2004; Dierks et al, 2005). These conditioned media were
recovered from HeLa cells that had been transfected with
either wild-type SUMF1 cDNA or the SUMF1C336R mutant
cDNA. The sulfatase activities were measured as previously
described (Cosma et al, 2004), using specific substrates
(Figure 3A). Enhancement of sulfatase activity was detected
after the uptake of SUMF1 and not after the uptake of the
SUMF1C336R mutant, with respect to the basal levels of the
transfected sulfatases. Since IDS, SGSH and other sulfatases
are also secreted and taken up, we wanted to be certain that
these enhanced sulfatase activities measured in the Cos7 cells
were actually due to uptake of SUMF1 and not to the uptake
of endogenous sulfatases secreted into the conditioned med-
ium by the HeLa cells. We thus used a lentiviral vector
expressing SUMF1-3xFlag to transduce two different human
MPSII and MPSIIIA fibroblast lines. MPSII and MPSIIIA are
two mucopolysaccharidoses in which the IDS and SGSH
enzymes, respectively, are inactive (Neufeld and Muenzer,
2001). The transduced fibroblasts were used as the SUMF1-
producing cell lines so as to obtain medium containing active
SUMF1 and inactive IDS or SGSH. MSD-recipient cells were
incubated with these conditioned media. IDS activity was
measured in the cell line cultured in the SUMF1-conditioned
medium produced from the MPSII (II-1S1 and II-2S1)-trans-
duced cells, whereas SGSH activity was measured in the MSD
cell lines incubated in the SUMF1-conditioned medium
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Figure 3 SUMF1 is enzymatically active following its uptake. (A) After its uptake, SUMF1 enhances the activity of transfected sulfatases. Cos7
cells were transfected with IDS, SGSH and ARSA cDNAs, and after 24 h, were incubated with medium containing SUMF1 or the inactive
SUMF1C336R mutant. Sulfatase activities were measured in cellular extracts and compared with the activities in the extracts prepared from
non-transfected cells (NT) and from sulfatase-transfected cells without SUMF1 uptake. (B) SUMF1 is taken up and can partially rescue sulfatase
activities in MSD fibroblasts. Two different MPSII (II-1, II-2) and MPSIIIA (IIIA-1, IIIA-2) cell lines were transduced with a lentiviral vector
carrying SUMF1-3xFlag cDNA to generate the conditioned-medium-producing II-1S1, II-2S1, IIIA-1S1 and IIIA-2S1 cells. The IDS and SGSH
activities were analyzed in cellular pellets of producing cells and of MSD (p.S155Pþ S155P)-recipient fibroblasts. For ARSC activity, the
producer cell line was the HL3xFS1 clone, and ARSC activity was evaluated in recipient cells and in control cells (MSD incubated in HeLa
medium). Expression of SUMF1-Flag (producing cells, upper panels) and its uptake (recipient cells, lower panel) was also evaluated by
Western blotting using an anti-Flag antibody. Western blotting with an anti–tubulin antibody provided the loading controls. (C) Uptake of
SUMF1 in Sumf1/ MEFs cultured in media collected from II-2S1 (for IDS activity), from IIIA-2S1 (for SGSH activity) and from HL3xFS1 (for
ARSC activity) cells. The IDS, SGSH and ARSC activities in Sumf1/ and wild-type MEFs are shown. (D) Uptake of SUMF1 in MSD fibroblasts
and Sumf1/ MEFs overexpressing IDS. The MSDþ IDS-recipient cells were cultured in SUMF1-conditioned medium collected from II-2S1
and II-1S1-producing cells. The Sumf1/þ IDS-recipient cells were cultured in SUMF1-conditioned medium collected from Ids/ MEFs
transduced with a lentivirus overexpressing SUMF1 cDNA. The IDS activities are expressed as percentages of the increased activities of the
recipient cells cultured in the SUMF1-conditioned medium versus the activity measured in the recipient cells cultured in non-conditioned
medium.
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produced from the MPSIIIA-transduced cells (IIIA-1S1 and
IIIA-2S1). A partial rescue of both enzymatic activities was
detected (Figure 3B). The IDS and SGSH activities measured
in the MSD cell lines after uptake were higher with respect to
the basal levels for both of these enzymes. SUMF1 expression
in MPSII and MPSIIIA fibroblasts and its uptake into the MSD
cell lines was also investigated by Western blotting
(Figure 3B). In addition, to be further sure that the effects
seen were due to SUMF1 uptake, we investigated the rescue
of a sulfatase activity that is not secreted, ARSC (Ballabio and
Shapiro, 1995). We thus incubated the MSD cell lines with
SUMF1-conditioned medium from the HL3xFS1 clone. We
measured a high level of ARSC activity after uptake in the
MSD cell line. The levels detected were also much higher
than the endogenous enzymatic ARSC activity of the MSD
fibroblasts incubated with control HeLa cell-conditioned
medium (Figure 3B). Finally, we performed uptake experi-
ments using MEFs from Sumf1/ mice as recipient cells.
These cells have the main advantage of not having any
residual sulfatase activity (Settembre et al, 2007). SUMF1
was produced from the MPSII- and MPSIIIA-producing cells
and from the HL3xFS1 clone. A partial rescue of the IDS,
SGSH and ARSC activities in the extracts from the recipient
cells was seen (Figure 3C). The activities of IDS and SGSH
were higher with respect to the basal levels in the Sumf1/
MEFs; however, they were lower with respect to the levels
measured in the wild-type MEFs. Of note, after the uptake of
SUMF1, the ARSC activity was higher with respect to ARSC
levels measured in both the Sumf1/ and wild-type MEFs
(Figure 3C). Likewise, although we clearly detected a rescue
of the activity of different sulfatases in the MSD fibroblasts
(Figure 3B), the measured enzymatic levels in the comple-
mented MSD cell lines were lower with respect to the mean
activities in wild-type fibroblasts (IDS was about 20% with
respect to wild type, SGSH about 27% and ARSC about 80%;
data not shown). Thus, to better detect the enhancing activity
of internalized SUMF1, we decided to overexpress one sulfa-
tase, IDS, in recipient MSD and Sumf1/ cell lines using a
lentiviral vector. The IDS-transduced MSD cells were incu-
bated with SUMF1-conditioned media from each of the two
different MPSII-producing cell lines: the IDS activities were
increased by 30 and 76% in the recipient MSD cells after
SUMF1 uptake (Figure 3D, II-2S1 and II-1S1, respectively).
Similarly, the IDS-transduced Sumf1/ MEFs were cultured
with SUMF1-conditioned medium produced from Ids/
MEFs transduced with a lentivirus expressing SUMF1. After
SUMF1 uptake, the IDS activity was increased by 90% in the
recipient Sumf1/ cells (Figure 3D, Ids/S1). Altogether,
these data demonstrate that SUMF1 is active after its uptake,
as it can still enhance sulfatase activities.
Glycosylation of SUMF1 is not essential for its secretion
and function
SUMF1 is N-glycosylated on its asparagine 141 (N141;
Preusser-Kunze et al, 2005). To analyze the role of the
glycosyl residues in the secretion and activity of SUMF1, we
mutated N141 to alanine in the SUMF1-3xFlag cDNA. The
SUMF1N141A mutant protein was detected in cellular ex-
tracts of HeLa cells transfected with the mutated cDNA and
showed a profile of migrating bands slower with respect to
wild-type SUMF1 (Figure 4A, lanes 1 and 3). SUMF1N141A is
not sensitive to EndoH digestion (Figure 4A, lane 4) and the
Western blotting showed a pattern of bands equivalent to
those of SUMF1 digested with EndoH (Figure 4A, compare
lanes 1 and 4), further demonstrating that SUMF1N141A is
not glycosylated. In addition, the protein correctly localized
in the ER when the mutant cDNA was transfected in HeLa
cells (Figure 4B). Surprisingly, SUMF1N141A was still
secreted into the medium, and furthermore, the secreted
mutant was insensitive to the digestion with PNGase F, as
expected (Figure 4C, upper panel). This enzyme cleaves
between the innermost GlcNAC and asparagine residues of
the glycosylated content and has previously been demon-
strated to digest the secreted SUMF1 forms (Preusser-Kunze
et al, 2005). Finally, we did not detect uptake of
SUMF1N141A in HeLa cells cultured in medium containing
the mutant SUMF1 form (Figure 4C, lower panel).
To investigate whether the uptake of SUMF1 is dependent
on its glycosylation, we digested the conditioned medium
recovered from the HL3xFS1 clone with the PNGase F enzyme.
Western blotting of the treated and non-treated media was
performed with an anti-Flag antibody and a fast migrating
band corresponding to the digested SUMF1 form was detected
(Figure 4D, upper panel). Thus, we cultured HeLa-recipient
cells in the HL3xFS1-conditioned medium that had been
digested and not been digested with PNGase F. Western
blotting of the protein extracts demonstrated the uptake of
the non-digested SUMF1 exclusively (Figure 4D, lower panel).
The mass spectrometry analysis is also of note, where we saw
that in the HeLa-recipient cells, the glycosylated SUMF1 forms
corresponding to bands 1 and 2 were present, whereas band 3,
corresponding to non-glycosylated SUMF1, was not seen
(Supplementary Figure 1). Thus, SUMF1 can be taken up
into the cells only if its glycosylation is preserved. These
results demonstrate that non-glycosylated SUMF1 can be
secreted into the medium, but it cannot be taken up, at least
under these experimental conditions. Finally, to further con-
firm these observations, we expressed Xenopus Sumf1
(xSumf1) cDNA in HeLa cells. xSumf1 does not contain
N-glycosylation since N141 is not conserved (Dierks et al,
2005). The xSumf1 protein was well expressed in the HeLa
cells, as shown by Western blotting (Figure 4A, lane 5) and it is
not sensitive to EndoH digestion, further demonstrating that it
is not glycosylated (Figure 4A, lane 6). Furthermore, the
xSumf1 protein localized to the ER, as shown by the merged
signal with ERAB (Figure 4E). Thus, we checked its secretion
and uptake by Western blotting. We found efficient secretion
from HeLa cells (Figure 4F, upper blot), but no uptake into
HeLa-recipient cells (Figure 4F, lower blot).
Finally, since we discovered that both SUMF1N141A and
xSumf1 localize to the ER, we wondered if they were still
active and thus, if they retained their enhancing activities on
the sulfatases. Transient transfections were carried out in
HeLa cells of SUMF1N141A and xSumf1, or as controls,
(Drosophila) dSumf1 and (human) hSUMF1, with either
ARSC or IDS cDNAs. SUMF1N141A and xSumf1 retained
50 and 62% of enhancing activity on ARSC, and 35 and
40% for IDS, respectively, with respect to wild-type hSUMF1
(Figure 4G). As a control, dSumf1 had 17% activity on ARSC
and 25% on IDS, with respect to wild-type hSUMF1, similar
to our previous findings (Cosma et al, 2003). These results
demonstrate that not only does non-glycosylated SUMF1
localize to the ER, but it also still retains its enhancing
activity on the sulfatases.
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SUMF1 is secreted and taken up in vivo
Having shown the secretion and uptake of SUMF1 in cultured
cells, we next tested whether this effect applies also in vivo.
Thus, we produced an adeno-associated viral vector, AAV2/8,
expressing SUMF1-3xFlag from the thyroxine-binding
globulin (TBG) promoter. The AAV2/8 serotype transduces
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cellular extracts were treated with EndoH, as indicated. The samples were analyzed by Western blotting and the filters were decorated with an
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transfected HeLa cells. Media were collected and concentrated. The conditioned medium containing SUMF1N141A was digested with PNGase
F. The samples were analyzed by Western blotting using an anti-Flag antibody (upper panels). For uptake, HeLa cells were cultured for 12 h in
concentrated medium collected from one T75 flask of confluent cells transfected with SUMF1-3xFlag or SUMF1421G4A,422C4A-3xFlag. The
protein extracts were analyzed using anti-Flag and anti–tubulin antibodies (lower panels). (D) SUMF1 secreted from HL3xFS1 contains PNGase
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hepatocytes with high efficiency and the TBG promoter is
liver specific; therefore, SUMF1 can only be expressed by the
liver (Cardone et al, 2006). We transduced 2-month-old wild-
type mice (n¼ 3) by tail-vein injection with a total of
2.81011 viral particles. Ten days after transduction, the
mice were bled and killed. Western blotting was performed
using an anti-Flag antibody on the liver homogenates and
on the immunoprecipitates from the serum. A SUMF1 signal
was clearly detected in the liver and serum of the trans-
duced animals (Figure 5A, left-hand panels). To determine if
SUMF1 was taken up in the non-transduced organs of these
mice, we analyzed the presence of the protein in bone
marrow cells after immunoprecipitation with an anti-Flag
antibody. A clear signal was detected in all of the trans-
duced animals (Figure 5A, right-hand panel). Furthermore,
we analyzed the uptake of SUMF1 by immunofluorescence
in the non-transduced tissues, including spleen, lung and
kidney, using an anti-Flag monoclonal antibody. We de-
tected positive signals in the liver, the producer organ,
and also in the spleen, kidney and lung, indicating that
SUMF1 was taken up into these tissues from the serum.
Again, SUMF1 localized to the ER, as seen by the merge
with the signals that were detectable with the ER marker
ERAB, by both indirect light and confocal microscopy
techniques (Figure 5B). To determine if SUMF1 was also
active after its uptake, we temporal-vein injected one wild-
type and two Sumf1/ mice littermates at 2 days of age.
Ten days after the injections, the transduced and control
littermates (non-transduced mice) were killed and the activ-
ity of ARSC, the non-secreted sulfatase, was measured. The
use of ARSC here was specifically chosen, again since it is
not secreted, and this allows the conclusion that the rescue
is due to the uptake of SUMF1 and not to the uptake of the
secreted sulfatases produced in the liver. The transduction
efficiencies were different in the two injected Sumf1/
mice, as shown by the activities measured in the livers
(Figure 5C). Surprisingly, we detected a significant rescue of
ARSC activity in the kidneys of the two Sumf1/ knock-
out mice and an increased activity in the kidney of the
treated wild-type mouse (Figure 5C). These data demon-
strate that once secreted from a producing organ into the
serum, SUMF1 is not only taken up by other distant tissues,
but it also relocalizes to the ER, while enhancing the activity
of the sulfatases.
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Figure 5 SUMF1 is taken up into mice tissues. (A) Uptake and secretion of SUMF1 in tissues of wild-type mice. AAV2/8TBG-3xFS1 particles
(2.81011 total) were tail-vein injected into three C56BL/6 mice. Ten days later, control (non-injected) and injected mice were killed and their
tissues were analyzed. Expression of SUMF1 was detected in the transduced livers by Western blotting and secretion of SUMF1-Flag was
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wild-type mouse at p2. Ten days later, transduction and ARSC activities were assayed in their liver and kidney homogenates.
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The uptake of SUMF1 is receptor mediated
We next investigated how SUMF1 is taken up into cells. The
sulfatases are internalized from the plasma into cells through
the MPR, and by a low-affinity process through the MR (Lee
et al, 2002; Ni et al, 2006). Therefore, we wanted to see if
SUMF1 follows the same path, by using receptor-competition
assays in the uptake experiments. Human wild-type fibro-
blasts were cultured in SUMF1-conditioned medium contain-
ing two concentrations of yeast mannan (2 and 3 mg/ml), a
specific competitor for binding to the MR (Taylor and
Drickamer, 1993). Alternatively, these cells were cultured in
medium containing SUMF1 plus anti-MR-antibody (1 mg/
ml). The uptake of SUMF1 was drastically reduced under
both of these conditions (Figure 6A, compare lane 1 with
lanes 2–4). In contrast, when the cells were cultured in
SUMF1-conditioned medium plus mannose 6-phosphate
(10 mM), which competes for the MPR (Hiesberger et al,
1998), almost no reduction in uptake was detected
(Figure 6A, compare lanes 5 and 8). Finally, when the cells
where cultured in SUMF1-conditioned medium plus both
mannan (3 mg/ml) and mannose 6-phosphate (10 mM), the
uptake of SUMF1 was fully abolished (Figure 6A, compare
lanes 5 and 7). The loading control used here was hybridiza-
tion with an anti–tubulin antibody. These data demonstrate
that in human fibroblasts, SUMF1 is taken up via the MR,
although a part is also taken up via the MPR, albeit with
low affinity.
We obtained similar results in MEFs. Wild-type and MR/
MEFs were incubated with SUMF1-conditioned medium. We
detected a reduction in the uptake of SUMF1 into the MR/
MEFs, with respect to the wild-type cells (Figure 6B, lanes
1–4). In contrast, there was no reduction in SUMF1 uptake
detected in the double knock-out MPR46/MPR300/
MEFs, with respect to wild-type cells (Figure 6B, lanes 5–7).
However, a reduction in SUMF1 uptake was detected
when the MPR46/MPR300/ MEFs were cultured in
SUMF1-conditioned medium plus mannan (2 mg/ml;
Figure 6B, lane 8). In conclusion, in MEFs and human
fibroblasts, uptake of SUMF1 is mediated principally by the
MR, and to some extent by the MPR.
Discussion
Here, we have demonstrated that SUMF1 is secreted into and
taken up from the medium in different types of cultured cells,
and from the plasma in tissues of AAV-transduced mice.
Furthermore, by using the SUMF1N141A mutant and the
Xenopus Sumf1 cDNAs, both coding for the proteins lacking
glycosylation, we have demonstrated that SUMF1 secretion is
independent of its sugar content. We also show that the
uptake, which is impaired by the lack of glycosylation, is
mainly mediated via the MR, and, to some extent, by the
MPR. Strikingly, once taken up, SUMF1 travels through the
cell until it reaches the ER. Finally, we demonstrate that in
Cos7 cells, MSD fibroblasts, Sumf1/ MEFs and in vivo in
Sumf1/ mice, SUMF1 can enhance at least four different
sulfatase activities after being taken up.
To date, the only proteins, which have been extensively
characterized as being able to move from the external envir-
onment into cells via the plasma membrane to reach the ER
are some of the toxins (Sandvig and van Deurs, 2000). In
addition, autocrine motility factor has also been seen to be
endocytosed to the smooth ER (Lagana et al, 2005), and ER-
mediated phagocytosis of red blood cells has been described
as a source of iron from the internalized hemoglobin
(Desjardins, 2003). In the case of toxin endocytosis, they
are obviously pirating of a physiological route in cells. Here,
however, we are facing a mammalian protein that is appar-
ently using its own route to reach the ER compartment. Two
principal questions thus arise: (i) how does SUMF1 get
β-Tubulin
WT + + + +
Fibroblasts
Fibroblasts
1 2 3 4
–
– – –
+ + –
+Anti-MR
Mannan
SUMF1
Medium
HL3xFS1 + + + +
WT + + + +
Mannan – + + –
Mannose-6-P – – + +
β-Tubulin
SUMF1
5 6 7 8
Medium
HL3xFS1 + + + +
MR –/–
MPR –/–
–
–
+ – +
MEF
SUMF1
WT MEF + + –
β-Tubulin
Medium
HL3xFS1 – – + +
1 2 3 4
Medium
HL3xFS1 + – + +
Mannan – – – +
β-Tubulin
SUMF1
WT MEF + + – –
– – + +
MEF
5 6 7 8
A B
Figure 6 Uptake of SUMF1 is receptor mediated. (A) MR and MPR competition assays in human fibroblasts. Wild-type fibroblasts were
cultured in SUMF1-Flag-conditioned medium collected from the HL3xFS1 clone, in the absence and presence of mannan (2 and 3 mg/ml),
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secreted from the ER of cells and reach the ER of other cells?
(ii) Does SUMF1 behave as a paracrine agent, or in other
words, is the transit of SUMF1 through the cells a physiolo-
gical condition?
For the former, we have only just started to determine how
SUMF1 leaves the ER to reach the extracellular environment,
and then how it gets back into the ER. SUMF1 does not have
an ER-retention signal, although it resides in the lumen of the
ER. Given the extraction conditions that are needed to re-
cover SUMF1 from cells, we would predict that SUMF1 is
associated with membranes. Therefore, our hypothesis would
be that since SUMF1 does not have an ER-retention signal, it
must be associated to ER membranes via an unknown inter-
actor that acts as a receptor to retain it in the ER. It has been
suggested that transport of glycoproteins out of the ER is
regulated by lectins, which specifically bind to glycoproteins
and function as receptors. The role of these receptor-like
lectins is to retain glycoproteins rather than transport them
actively (Helenius, 1994; Nyfeler et al, 2006). Thus, many
proteins would not move out of the ER using a bulk-flow
mechanism. In contrast, their trafficking might be regulated
by receptors, which harmonize their retention and escape.
We have demonstrated that non-glycosylated Xenopus Sumf1
and an N-glycosylation mutant of human SUMF1 can still be
secreted. Thus, our prediction is that glycosylation is impor-
tant for SUMF1 to be retained in the ER by an as yet unknown
receptor-like interactor, although a fraction of the SUMF1 can
be secreted. It will be interesting to demonstrate if non-
glycosylated SUMF1 escapes the ER more efficiently with
respect to its glycosylated form. Interestingly, non-glycosy-
lated SUMF1 is still able to activate the sulfatases, as shown
for the SUMF1N141A mutant and for the natural xSumf1.
Thus, we would predict that non-glycosylated SUMF1 folds
correctly and glycosylation has a role in the retention of
SUMF1 in the ER exclusively, rather than for its activity. It
has been postulated that although most glycoproteins need
their N-linked oligosaccharides during folding, the degree of
dependence is variable. Some proteins display total or only
partial misfolding in the absence of sugars; however, there
are numerous proteins, which fold correctly without their
N-linked sugars (Helenius, 1994).
Once SUMF1 is secreted, it can be taken up by other cells,
including immortalized cell lines, MEFs and human fibro-
blasts, as we have also confirmed by mass spectrometry
analysis. Our receptor-competition and uptake data in the
MR/ knock-out MEFs and in the MPR46/MPR300/
double knock-out MEFs show that SUMF1 is internalized via
the MR, and to some extent, via the MPR. Under our cellular
conditions, the lack of sugars, that is, of the mannose con-
tent, is crucial to abrogate the uptake. However, we cannot
exclude that in different cell lines, alternative compensatory
mechanisms can allow partial uptake of SUMF1. The MR
mediates endocytosis of glycoproteins with terminal man-
nose, fucose, N-acetylglucosamine and/or glucose residues
(Stahl, 1990). Furthermore, the MR mediates the clearance of
glycoproteins with high mannose oligosaccharides, such as
lysosomal enzymes (Stahl, 1990). A deficiency in the MR in
mice affects the uptake of multiple glycoproteins from plasma
into tissues (Lee et al, 2002). In addition, the MR mediates
uptake of the toxin ricin (Simmons et al, 1986). Here, we
have seen that SUMF1 is also taken up via the MR, which
appears to be the route that is used by ricin, which enters the
cells via the MR, travels across the Golgi complex and reaches
the ER. In contrast, MPR 300 mediates the uptake of lysoso-
mal enzymes, including the sulfatases, which bear the man-
nose-6-phosphate marker (Ni et al, 2006). From the crystal
structure and mass spectrometry, it appears that SUMF1 does
not contain mannose 6-phosphate (Dierks et al, 2005);
furthermore, SUMF1 was not included in a recent study in
which all of the lysosomal and non-lysosomal proteins with
mannose-6-phosphate residues were fished out by affinity
chromatography (Sleat et al, 2006). Our data clearly demon-
strate a very low affinity of SUMF1 for the MPR, suggesting
that the MPR might only have a compensatory role. There is
also the possibility that SUMF1 is internalized via a piggy-
back mechanism, along with the sulfatases. We have recently
demonstrated that a stable complex can be formed between
SUMF1, SUMF2 and the sulfatases; however, we have never
been able to detect a stable complex between SUMF1 and the
sulfatases (Zito et al, 2005). To exclude the possibility of such
a piggyback mechanism, we also examined the uptake of
SUMF1 in MEFs that we established from an Sumf2/
mouse (Annunziata et al, unpublished data). We chose the
Sumf2/ MEFs since the triple complex (SUMF1/SUMF2/
sulfatase) is abrogated here, while it would be impossible to
have a cell line without all of the sulfatases. In these Sumf2/
MEFs, the uptake of SUMF1 is completely normal, as SUMF1
is taken up as in wild-type cells, thus excluding a piggyback
mechanism of uptake (Supplementary Figure 4). However,
the question as to how SUMF1 travels from the plasma
membrane to the ER remains completely open. The toxins
were the first molecules that were demonstrated to enter the
cell via the endosomes and to get transported ‘back’ to the
Golgi complex, and thence to the ER (Sandvig and van Deurs,
2000). This retrograde transport from the Golgi complex to
the ER could be either COP-I dependent or independent. The
COP-I-independent pathway is regulated by the GTPase Rab6,
and it is used by Golgi glycosylation enzymes, Shiga toxin (ST)
and ricin (Girod et al, 1999). In contrast, the lectin ERGIC-53,
which is a cargo-receptor for glycoproteins, and cholera toxin
use a COP-I-dependent pathway to reach the ER (Girod et al,
1999; Sandvig and van Deurs, 2000). It will be fascinating to
identify which pathway SUMF1 uses to travel across the ER and
the Golgi complex, and thus to dissect out its anterograde
and retrograde transport.
A further important question is to understand why SUMF1
acts as a paracrine agent, and if the movement of SUMF1
from the ER of one cell to the ER of another cell is a
physiological condition. We have seen that endogenous
SUMF1 secretion occurs and the secreted SUMF1 can be
taken up by MSD fibroblasts. At present, we cannot demon-
strate that this also applies in vivo, since we would need to
generate a tissue-specific Sumf1/ mouse to follow the
trafficking of SUMF1 from the wild-type to the knock-out
tissues. However, what is clear is that SUMF1 is enzymati-
cally active after its uptake, a situation that we have demon-
strated in several cell lines and in Sumf1/ mice. Thus,
although many proteins that reach the ER get degraded by the
proteasome, including the toxins, this is not the destiny of
SUMF1: we can detect SUMF1 in the ER by Western blotting
and indirect immunofluorescence, and most importantly, we
have demonstrated that the internalized SUMF1 can enhance
sulfatase activities within the recipient cell. A provocative
hypothesis would be that SUMF1 works as a hormone-like
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factor in the regulation of sulfatase activities, while working
as a paracrine agent. In this respect, it will be intriguing to
determine if SUMF1 modulates the function of the sulfatases
in different tissues and cells in a paracrine manner, or if it
mediates signalling pathways.
Finally, our findings have potential application in the
therapy of MSD. We have demonstrated that engineering
the liver to produce SUMF1 in the Sumf1/ knock-out
mouse model allows secretion of the protein and cross-
correction of sulfatase activities in non-transduced tissues.
Thus, it will be possible in the near future to set up gene
therapy and enzyme replacement therapy protocols to treat
first the Sumf1/ mouse model, and then, in the long term,
patients suffering from this severe disease.
Materials and methods
Cell lines, cDNAs, AAV and lentivirus production, Western
blotting and immunoprecipitation, mass spectrometry
analysis and endoglycosidase treatment of cellular extracts,
and media
For details, see Supplementary data.
Cells and tissues immunofluorescence, transfection
and sulfatase enzymatic analysis
These experiments were carried out as previously described (Cosma
et al, 2004; Zito et al, 2005; Cardone et al, 2006). All animal
experiments were carried out in accordance with Italian law.
SUMF1 uptake assay
Recipient cells, MEFs, human fibroblasts, Cos7 and HeLa cells were
grown to 90% confluency in DMEM (Invitrogen, NY, USA), 10%
fetal calf serum (Euroclone, Pero, MI, Italy) at 371C, 5% CO2 in six-
well plates (Costar, Cambridge, MA, USA). The cells were incubated
for 12 h in SUMF1-conditioned medium collected from different
subconfluent producing cells (HL3xFS1, HepG2, II-1-S1, II-2-S1,
IIIA-1-S1, IIIA-2-S1,) cultured in T75 flasks (Costar). The recipient
cells were washed twice with PBS, trypsinized and lysed in RIPA
buffer (150 mM NaCl, 50 mM Tris–HCl, pH 7.5, 500 mM EDTA, 0.1%
SDS, 1% Triton-X100 and 1% sodium deoxycholate containing a
proteinase inhibitor cocktail; Sigma, St Louis, MO, USA). Protein
concentrations were measured in total homogenates by the
Bradford assay (Bio-Rad, Hercules, CA). SUMF1 uptake was
analyzed by Western blotting and by testing the sulfatase activities.
Additional details are provided in the Supplementary data.
Receptor-competition assay
Recipient cells were cultured for 12 h in SUMF1-conditioned
medium collected from the HL3xFS1 clone in the presence of
limiting amounts (100 ng/ml, final concentration) of cycloheximide
(Sigma), and in the absence or presence of the following receptor
inhibitors: 2 or 3 mg/ml yeast mannan (Sigma) (competitive
inhibitor of the MR), 10 mM mannose 6-phosphate (Sigma)
(competitor for the MPR) or 1 mg/ml anti-MR IgG. After 12 h, the
recipient cells were washed twice with PBS and trypsinized. The
SUMF1 uptake in the cell extracts was analyzed by Western
blotting.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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